Celgene was among the investors helping the cancer cell-therapy developer increase its total funding to approximately $110m.
US-based cell therapy developer Nohla Therapeutics completed a $45m series B round on Tuesday featuring pharmaceutical firm Celgene.
Alexandria Venture Investments, part of life sciences real estate investment trust Alexandria Real Estate Equities, also invested, as did financial services group Fidelity Management and Research, Arch Venture Partners, 5AM Ventures and AML Biotech Partners.
Nohla is working on cell therapies for sufferers of diseases such as cancer. They are intended to help bone marrow function in the short term, and to…
